Study to Evaluate the Effects of NMRA-323511 Among Healthy Elderly and Adults With Agitation Associated With Dementia Due to Alzheimer's Disease

Last updated: November 19, 2025
Sponsor: Neumora Therapeutics, Inc.
Overall Status: Completed

Phase

1

Condition

Memory Loss

Manic Disorders

Dementia

Treatment

NMRA-323511

Placebo

Clinical Study ID

NCT06546995
NMRA-323511-104
  • Ages 55-90
  • All Genders
  • Accepts Healthy Volunteers

Study Summary

This study consists of 2 parts, Part A and Part B. Part A is a single center, randomized, double-blind, placebo-controlled cohort designed to evaluate the safety, tolerability, and pharmacokinetics (PK) of NMRA-323511 among healthy elderly.

Part B is a multicenter, randomized, double-blinded, placebo-controlled, parallel-group cohort to evaluate the safety, tolerability, and efficacy of NMRA-323511 among adults with Agitation Associated with Dementia due to Alzheimer's Disease.

Part A consists of a Screening Period (up to 28 days), a 10-day Treatment Period, and a 10- day Follow-up clinic visit after last dose of study treatment.

Part B consists of a Screening Period (up to 28 days), an 8-week Treatment Period, and a 10-day Follow-up clinic visit after last dose of study treatment.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Part A

  • Healthy participants

  • Age 65 to 80 years

  • Body mass index (BMI) ≥18.0 and ≤32.0 kg/m^2 at the screening and check-in visit

Part B

  • Participants aged 55 to 90 years

  • Diagnosis of probable AD or Alzheimer's clinical syndrome according to the NationalInstitute of Aging-Alzheimer's Association criteria at least 12 months prior toscreening

  • Agitation meets the International Psychogeriatric Association (IPA) consensusdefinition

  • Mini-Mental State Examination (MMSE) score = 5 - 24 (mild to severe dementia) atscreening

Exclusion

Exclusion Criteria:

Part A

  • Participant is actively suicidal

  • Is mentally or legally incapacitated or has significant emotional problems at thetime of the screening visit

  • Diagnosis of epilepsy taking anticonvulsants for seizure control, history ofseizures

Part B

  • Dementia or memory impairment due to a reason other than AD

  • Clinically significant neurologic disorder other than AD

  • Have any clinically significant and uncontrolled medical condition

Note: Other protocol defined inclusion/exclusion criteria may apply

Study Design

Total Participants: 96
Treatment Group(s): 2
Primary Treatment: NMRA-323511
Phase: 1
Study Start date:
July 09, 2024
Estimated Completion Date:
November 19, 2025

Connect with a study center

  • Neumora Investigator Site

    Chandler, Arizona 85286
    United States

    Site Not Available

  • Neumora Investigator Site

    Tempe, Arizona 85283
    United States

    Site Not Available

  • Neumora Investigator Site

    Chandler 5289282, Arizona 5551752 85286
    United States

    Site Not Available

  • Neumora Investigator Site

    Tempe 5317058, Arizona 5551752 85283
    United States

    Site Not Available

  • Neumora Investigator Site

    Costa Mesa, California 92626
    United States

    Site Not Available

  • Neumora Investigator Site

    Lomita, California 90717
    United States

    Site Not Available

  • Neumora Investigator Site

    Walnut Creek, California 94596
    United States

    Site Not Available

  • Neumora Investigator Site

    Costa Mesa 5339840, California 5332921 92626
    United States

    Site Not Available

  • Neumora Investigator Site

    Lomita 5367767, California 5332921 90717
    United States

    Site Not Available

  • Neumora Investigator Site

    Walnut Creek 5406990, California 5332921 94596
    United States

    Site Not Available

  • Neumora Investigator Site

    Bradenton, Florida 34205
    United States

    Site Not Available

  • Neumora Investigator Site

    Greenacres City, Florida 33467
    United States

    Site Not Available

  • Neumora Investigator Site

    Hallandale Beach, Florida 33009
    United States

    Site Not Available

  • Neumora Investigator Site

    Hialeah, Florida 33016
    United States

    Site Not Available

  • Neumora Investigator Site

    Miami, Florida 33155
    United States

    Site Not Available

  • Neumora Investigator Site

    Miami Springs, Florida 33166
    United States

    Site Not Available

  • Neumora Investigator Site

    Orlando, Florida 32807
    United States

    Site Not Available

  • Neumora Investigator Site

    Pembroke Pines, Florida 33024
    United States

    Site Not Available

  • Neumora Investigator Site

    Bradenton 4148708, Florida 4155751 34205
    United States

    Site Not Available

  • Neumora Investigator Site

    Greenacres City 4157467, Florida 4155751 33467
    United States

    Site Not Available

  • Neumora Investigator Site

    Hallandale 4157898, Florida 4155751 33009
    United States

    Site Not Available

  • Neumora Investigator Site

    Hialeah 4158476, Florida 4155751 33016
    United States

    Site Not Available

  • Neumora Investigator Site

    Miami 4164138, Florida 4155751 33126
    United States

    Site Not Available

  • Neumora Investigator Site

    Miami Springs 4164223, Florida 4155751 33166
    United States

    Site Not Available

  • Neumora Investigator Site

    Orlando 4167147, Florida 4155751 32807
    United States

    Site Not Available

  • Neumora Investigator Site

    Pembroke Pines 4168139, Florida 4155751 33024
    United States

    Site Not Available

  • Neumora Investigator Site

    Port Orange 4169156, Florida 4155751 32127
    United States

    Site Not Available

  • Neumora Investigator Site

    Atlanta, Georgia 30318
    United States

    Site Not Available

  • Neumora Investigator Site

    Atlanta 4180439, Georgia 4197000 30318
    United States

    Site Not Available

  • Neumora Investigator Site

    Honolulu, Hawaii 96817
    United States

    Site Not Available

  • Neumora Investigator Site

    Honolulu 5856195, Hawaii 5855797 96817
    United States

    Site Not Available

  • Neumora Investigator Site

    Boise, Idaho 83704
    United States

    Site Not Available

  • Neumora Investigator Site

    Boise 5586437, Idaho 5596512 83704
    United States

    Site Not Available

  • Neumora Investigator Site

    Belmont, Massachusetts 02478
    United States

    Site Not Available

  • Neumora Investigator Site

    Belmont 4930282, Massachusetts 6254926 02478
    United States

    Site Not Available

  • Neumora Investigator Site

    Troy, Michigan 48085
    United States

    Site Not Available

  • Neumora Investigator Site

    Troy 5012639, Michigan 5001836 48085
    United States

    Site Not Available

  • Neumora Investigator Site

    Toms River, New Jersey 08755
    United States

    Site Not Available

  • Neumora Investigator Site

    Toms River 4504476, New Jersey 5101760 08755
    United States

    Site Not Available

  • Neumora Investigator Site

    Brooklyn, New York 11229
    United States

    Site Not Available

  • Neumora Investigator Site

    East Syracuse, New York 13057
    United States

    Site Not Available

  • Neumora Investigator Site

    Brooklyn 5110302, New York 5128638 11229
    United States

    Site Not Available

  • Neumora Investigator Site

    East Syracuse 5116079, New York 5128638 13057
    United States

    Site Not Available

  • Neumora Investigator Site

    Charlotte, North Carolina 28204
    United States

    Site Not Available

  • Neumora Investigator Site

    Charlotte 4460243, North Carolina 4482348 28204
    United States

    Site Not Available

  • Neumora Investigator Site

    Mesquite, Texas 75149
    United States

    Site Not Available

  • Neumora Investigator Site

    Mesquite 4710826, Texas 4736286 75149
    United States

    Site Not Available

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.